

SANGINITA CHEMICALS LIMITED

(CIN: L24100GJ2005PLC047292)

Registered Office: 301, 3rd Floor, Shalin Complex, Sector - 11

Gandhinagar - 382 011 (Gujarat) Tele No: +079 2324 0270

Website: www.sanginitachemicals.co.in

E-mail: dbchavada@yahoo.co.in

11th July, 2025

To,
The National Stock Exchange of India Limited
Bandra Kurla Complex (Bandra East)
Mumbai-400051

SYMBOL: SANGINITA

Dear Sir,

Sub: Submission of Unaudited Financial Results for the Quarter ended on 30th June, 2025

With reference to our letter dated 1st July, 2025 informing the date of Meeting of Board of Directors of the Company and pursuant to Regulation 33 and Regulation 30 read with Para- A of Part -A of Schedule III of the SEBI (LODR) Regulations, 2015; please note that the Board of Directors in their meeting held today, have approved the Unaudited Financial Results for the Quarter ended on 30th June, 2025.

The meeting of Board of Directors commenced at 3.00 p.m. and concluded at 4.15 p.m.

We are enclosing herewith copy of said Unaudited Financial Results. We are also enclosing herewith copy of Limited Review Report of the Statutory Auditors of the Company on the aforesaid Unaudited Financial Results.

The Company operates in single segment i.e. "Chemical Business".

In terms of Regulation 32(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the Guidance Note as per SEBI circular dated 3rd May, 2018, we hereby undertake that there is no deviation/variation in utilization of issue proceeds. Please take note of the same.

Thanking you,

Yours faithfully,

For SANGINITA CHEMICALS LIMITED

DINESHSINH B CHAVADA (DIN: 01497977)
CHAIRPERSON AND MANAGING DIRECTOR



B. K. Chavda & Co.

Chartered Accountants

LIMITED REVIEW REPORT

To
The Board of Directors,
Sanginita Chemicals Limited
Gandhinagar

We have reviewed the accompanying statement of Unaudited Financial Results of **Sanginita Chemicals Limited** ("the Company"), for the Quarter ended on 30th June, 2025. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to Believe that the accompanying statement of unaudited financial results prepared in accordance With applicable Indian accounting standards ("IND AS") specified under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Gandhinagar
Date: 11th July, 2025



B. K. Chavda & Co.
Chartered Accountants
FRN: 125064W

CA B K Chavda (Partner)
(Membership No.: 116780)
UDIN: 25116780BMHGAW6428

SANGINITA CHECMIALS LIMITED

(CIN: L24100GJ2005PLC047292)

Registered Office:301, 3rd Floor, Shalin Complex, Sector-11, Gandhinagar -382011(Gujarat)**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER ENDED ON 30TH JUNE, 2025**

(Amount in Lakhs)

Particulars		Quarter ended on			Year ended on 31-03-2025 (Audited)
		30-06-2025 Unaudited	31-03-2025 Audited	30-06-2024 Unaudited	
I	Revenue from Operation	4591.04	4984.63	5694.77	22967.50
II	Other Income	37.36	1.44	3.64	26.17
III	Total Income (I + II)	4628.40	4986.07	5698.41	22993.67
IV	Expenses				
	Cost of Materials consumed	2269.14	2703.74	3743.65	13137.94
	Purchase of stock-in-trade	2193.98	2030.83	1769.15	8949.70
	Changes in inventories of finished goods, Stock-in-trade and work-in progress	(18.72)	69.13	(21.96)	49.62
	Employee benefits expense	28.91	35.88	28.14	133.43
	Finance Costs	53.04	58.74	64.02	243.60
	Depreciation and amortisation expense	54.24	47.09	26.44	167.75
	Other Expenses	37.76	47.70	47.02	228.75
	Total Expenses (IV)	4618.35	4993.11	5656.46	22910.79
V	Profit/(loss) before exceptional items and tax (III- IV)	10.05	(7.04)	41.95	82.88
VI	Exceptional Items	-	-	-	-
VII	Profit / (Loss) before tax (V-VI)	10.05	(7.04)	41.95	82.88
VIII	Tax expense [Less/(Add)]:				
	(1) Current Tax		(8.38)	10.78	9.51
	(2) Short/ (Excess) Provision of IT earlier years written back		0.13	(0.22)	0.13
	(3) Deferred Tax	(0.72)	6.58		11.39
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	10.77	(5.37)	31.39	61.85
X	Profit/(loss) from discontinued operations	-	-	-	-
XI	Tax expense of discontinued operations	-	-	-	-
XII	Profit/(loss) from Discontinued operations (after tax) (X-XI)	-	-	-	-
XIII	Profit/(loss) for the period (IX+XII)	10.77	(5.37)	31.39	61.85
XIV	Other Comprehensive Income				
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-



	B (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive Income for the period)	10.77	(5.37)	31.39	61.85
XVI	Earnings per equity share (for continuing operation):				
	(1) Basic &	0.04	(0.02)	0.12	0.24
	(2) Diluted	0.04	(0.02)	0.12	0.24
XVII	Earnings per equity share (for discontinued operation):				
	(1) Basic &		-	-	-
	(2) Diluted		-	-	-
XVIII	Earnings per equity share (for discontinued & continuing operations)				
	(1) Basic &	0.04	(0.02)	0.12	0.24
	(2) Diluted	0.04	(0.02)	0.12	0.24
XIX	Paid-up equity shares capital (Face Value Rs. 10/- each)	2590.16	2590.16	2590.16	2590.16
XX	Reserves excluding Revaluation Reserves as per Balance sheet of Previous accounting year	-	-	-	3024.31

Notes:

1. The above results have been reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on 11th July, 2025 and the same have been subjected to limited review by the Statutory Auditors of the Company.
2. The figures for the corresponding previous period have been restated/regrouped wherever necessary, to make them comparable.
3. In line with Ind AS - 108 - "Operating Segments", the operations of the company fall under chemical business which is considered to be the only reportable business segment.



FOR, SANGINITA CHEMICALS LIMITED

DINESHSINH B. CHAVADA
CHAIRPERSON & MANAGING DIRECTOR
(DIN: 01497977)

PLACE: GANDHINAGAR
DATED: 11TH JULY, 2025